Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Optimized Treatment and Regression of HBV-induced Compensated Liver Cirrhosis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01943617
Recruitment Status : Completed
First Posted : September 17, 2013
Last Update Posted : July 27, 2018
Sponsor:
Collaborators:
Peking University People's Hospital
RenJi Hospital
Peking University
Shanghai Zhongshan Hospital
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Shanghai Public Health Clinical Center
Nanfang Hospital of Southern Medical University
Sir Run Run Shaw Hospital
Beijing YouAn Hospital
Peking University First Hospital
Beijing 302 Hospital
Peking Union Medical College Hospital
Beijing Ditan Hospital
Beijing Tiantan Hospital
Huashan Hospital
Tongji Hospital
Tang-Du Hospital
Fifth Hospital of Shijiazhuang City
Logistics University of Chinese People's Armed Police Forces
The First Affiliated Hospital of Shanxi Medical University
The Affiliated Hospital of Yanbian University
Information provided by (Responsible Party):
Hong You, Beijing Friendship Hospital

Brief Summary:
Six hundreds patients with chronic hepatitis B clinically diagnosed as compensated liver cirrhosis are randomly assigned in a 1:1 ratio. One arm is entecavir alone for 2 years; the other is entecavir alone for the first 0.5 year, entecavir plus thymosin-α for 1 year, entecavir for another additional 0.5 year.Patients will be assessed at baseline, at every six months for blood cell count, liver function test, HBVDNA, AFP, prothrombin time, liver ultrasonography, and Fibroscan;

Condition or disease Intervention/treatment Phase
Liver Cirrhosis Drug: Entecavir Drug: Thymosin-α Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 606 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Optimized Treatment and Regression of HBV-induced Compensated Liver Cirrhosis
Study Start Date : June 2013
Actual Primary Completion Date : December 2016
Actual Study Completion Date : December 2016

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Cirrhosis
Drug Information available for: Entecavir

Arm Intervention/treatment
Active Comparator: Entecavir Therapy
Entecavir, 0.5mg, qd, oral, for 2 years
Drug: Entecavir
anti-viral therapy
Other Name: Entecavir dispersible tablets

Experimental: Entecavir plus thymosin therapy
Entecavir plus thymosin-α 1.6μg, Twice a week, ih, in the middle one year
Drug: Entecavir
anti-viral therapy
Other Name: Entecavir dispersible tablets

Drug: Thymosin-α
anti-viral and antitherapy
Other Name: Zadaxin




Primary Outcome Measures :
  1. Decompensated rate of Liver Cirrhosis after 2 years treatment [ Time Frame: 2 years ]
    Decompensated rate of Liver Cirrhosis (ascites, hepatic encephalopathy, esophageal varices bleeding and Hepatocellular Carcinoma) after 2 years treatment.


Secondary Outcome Measures :
  1. Child-Pugh and MELD scores [ Time Frame: 1 and 2-year ]
    The progress of Child-Pugh and MELD scores after 1 and 2-year treatment

  2. The HBV DNA undetectable rate [ Time Frame: 1 and 2-year ]
    The HBV DNA undetectable rate after 1 and 2-year treatment

  3. Liver stiffness measurement [ Time Frame: 1 and 2-year ]
    Liver stiffness measurement change after 1 and 2-year treatment.

  4. Quality of Life [ Time Frame: 1 and 2-year ]
    Quality of life after 1 and 2-year treatment by SF-36 and EQ-5D questionares



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Patients from age 18 to 65 years ;
  2. Male or female;
  3. Treatment-naive patients of clinically diagnosed as HBV-induced compensated cirrhosis(meet one of the following two criterions);

    1. endoscopy: esophageal varices , exclusion of noncirrhotic portal hypertension
    2. if no endoscopy,should meet two of the four Criterias:

      • Imaging (US, CT or MRI, et al) showing Surface nodularity: Echogenecity
      • Platelet (PLT) < 100×10 < 9 >/L , no other interpretation
      • Albumin (ALB) < 35.0 g/L, or International Standard Value (INR) > 1.3 (Prothrombin Time (PT) prolonged > 3s), or Cholinesterase (CHE) decrease
      • Liver stiffness measurement value > 12.4 kpa (ALT<5×ULN)
  4. HBeAg-positive, HBVDNA > 2×10<3> IU/ml or with HBeAg-negative patients, HBVDNA > 2×10<2> IU/ml;
  5. Agree to be followed up regularly;
  6. Signature of written inform consent.

Exclusion Criteria:

  1. Patients with decompensated cirrhosis: including ascites, hepatic encephalopathy, esophageal varices bleeding or other complications of decompensated cirrhosis or hepatocelluar carcinoma;
  2. Patients who are allergic to entecavir, thymosin or their components, and those considered not suitable for medicine in this study;
  3. Patients with HCV or HIV infection, alcoholic liver disease, autoimmune liver disease, genetic liver disease, drug-induced liver injury, severe non-alcoholic fatty liver disease or other chronic liver diseases;
  4. Patients with baseline AFP level higher than 100ng/ml and possible malignant lesion on image, or AFP level higher than 100ng/ml for more than three months;
  5. Creatinine > 1.5×ULN;
  6. Patients with other uncured malignant tumors;
  7. Patients with severe diseases of heart, lung, kidney, brain, blood system or other organs;
  8. Patients with any other reasons not suitable for the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01943617


Locations
Layout table for location information
China, Beijing
Beijing Ditan Hospital, Capital Medical University
Beijing, Beijing, China, 100015
Peking University First Hospital
Beijing, Beijing, China, 100034
302 Military Hospital Of China
Beijing, Beijing, China, 100039
Beijing Friendship Hospital, Capital Medical University
Beijing, Beijing, China, 100050
Beijing Tiantan Hospital, Capital Medical University
Beijing, Beijing, China, 100050
Peking University People's Hospital
Beijing, Beijing, China, 100050
Beijing YouAn Hospital, Capital Medical University
Beijing, Beijing, China, 100069
Peking Union Medical College Hospital
Beijing, Beijing, China, 100730
PeKing University
Beijing, Beijing, China, 100871
China, Guangdong
NanfangHospital,Southern Medical University
Guangzhou, Guangdong, China, 510515
China, Hebei
Shijiazhuang Fifth Hospital
Shijiazhuang, Hebei, China, 50021
China, Hubei
Tongji Hospital, Tongji Medical College ,Huazhong University of Science &Technology
Wuhan, Hubei, China, 300030
China, Jiangsu
Sir Run Run Shaw Hospital,School of Medicine,Zhejiang University
Hangzhou, Jiangsu, China, 310016
China, Jilin
The Affiliated Hospital of Yanbian University
Yanbian, Jilin, China, 133000
China, Shanghai
RenjiHospital,Shanghai Jiao Tong University,School of Medicine
Shanghai, Shanghai, China, 200032
Huashan Hospital FuDan University
Shanghai, Shanghai, China, 200040
Zhongshan Hospital Fudan University
Shanghai, Shanghai, China, 200040
Shanghai First People's Hospital
Shanghai, Shanghai, China, 200080
Shanghai Public Health Clinical Center
Shanghai, Shanghai, China, 201508
China, Shanxi
The First Hospital of Shanxi Medical University
Taiyuan, Shanxi, China, 30001
China, Tianjin
The Hospital Affiliated to Logistics University of Chinese People's Armed Police Force
Tianjin, Tianjin, China, 300162
Sponsors and Collaborators
Beijing Friendship Hospital
Peking University People's Hospital
RenJi Hospital
Peking University
Shanghai Zhongshan Hospital
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Shanghai Public Health Clinical Center
Nanfang Hospital of Southern Medical University
Sir Run Run Shaw Hospital
Beijing YouAn Hospital
Peking University First Hospital
Beijing 302 Hospital
Peking Union Medical College Hospital
Beijing Ditan Hospital
Beijing Tiantan Hospital
Huashan Hospital
Tongji Hospital
Tang-Du Hospital
Fifth Hospital of Shijiazhuang City
Logistics University of Chinese People's Armed Police Forces
The First Affiliated Hospital of Shanxi Medical University
The Affiliated Hospital of Yanbian University
Investigators
Layout table for investigator information
Principal Investigator: Hong You, Doctor Beijing Friendship Hospital

Layout table for additonal information
Responsible Party: Hong You, Vice-Director Liver Research Centre, Beijing Friendship Hospital
ClinicalTrials.gov Identifier: NCT01943617     History of Changes
Other Study ID Numbers: 2013ZX10002004-3
First Posted: September 17, 2013    Key Record Dates
Last Update Posted: July 27, 2018
Last Verified: July 2018

Keywords provided by Hong You, Beijing Friendship Hospital:
Liver Cirrhosis
Hepatitis B
Compensation
Efficacy

Additional relevant MeSH terms:
Layout table for MeSH terms
Fibrosis
Liver Cirrhosis
Pathologic Processes
Liver Diseases
Digestive System Diseases
Entecavir
Antiviral Agents
Anti-Infective Agents